Evidence map›Paper›PMID 36798816›Full record

ArticleFrontiers in oncology2023

A CT-based radiomics approach to predict immediate response of radiofrequency ablation in colorectal cancer lung metastases.

Haozhe Huang, Dezhong Zheng, Hong Chen, Chao Chen, Ying Wang, Lichao Xu, Yaohui Wang, Xinhong He, Yuanyuan Yang, Wentao Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Habitat-based radiomics analysis for evaluating immediate response in colorectal cancer lung metastases treated by radiofrequency ablation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Haozhe HuangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dezhong ZhengLaboratory for Medical Imaging Informatics, Shanghai Institute of Technical Physics, Shanghai, China.
Hong ChenDepartment of Medical Imaging, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao ChenDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Lichao XuDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yaohui WangDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xinhong HeDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yuanyuan YangLaboratory for Medical Imaging Informatics, Shanghai Institute of Technical Physics, Shanghai, China.
Wentao LiDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNShanghai Institute of Technical Physics · CNShanghai Jiao Tong University · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To objectively and accurately assess the immediate efficacy of radiofrequency ablation (RFA) on colorectal cancer (CRC) lung metastases, the novel multimodal data fusion model based on radiomics features and clinical variables was developed. Methods: This case-control single-center retrospective study included 479 lung metastases treated with RFA in 198 CRC patients. Clinical and radiological data before and intraoperative computed tomography (CT) scans were retrieved. The relative radiomics features were extracted from pre- and immediate post-RFA CT scans by maximum relevance and minimum redundancy algorithm (MRMRA). The Gaussian mixture model (GMM) was used to divide the data of the training dataset and testing dataset. In the process of modeling in the training set, radiomics model, clinical model and fusion model were built based on a random forest classifier. Finally, verification was carried out on an independent test dataset. The receiver operating characteristic curves (ROC) were drawn based on the obtained predicted scores, and the corresponding area under ROC curve (AUC), accuracy, sensitivity, and specificity were calculated and compared. Results: Among the 479 pulmonary metastases, 379 had complete response (CR) ablation and 100 had incomplete response ablation. Three hundred eighty-six lesions were selected to construct a training dataset and 93 lesions to construct a testing dataset. The multivariate logistic regression analysis revealed cancer antigen 19-9 (CA19-9, p<0.001) and the location of the metastases (p< 0.05) as independent risk factors. Significant correlations were observed between complete ablation and 9 radiomics features. The best prediction performance was achieved with the proposed multimodal data fusion model integrating radiomic features and clinical variables with the highest accuracy (82.6%), AUC value (0.921), sensitivity (80.3%), and specificity (81.4%). Conclusion: This novel multimodal data fusion model was demonstrated efficient for immediate efficacy evaluation after RFA for CRC lung metastases, which could benefit necessary complementary treatment.

Indexed as

clinical variablescolorectal cancercomputed tomography (CT)efficacy evaluationlung metastasisradiofrequency ablation (RFA)radiomics

Identifiers

PMID36798816
PMCPMC9927400
OpenAlexW4318592085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.